A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

PHASE3CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

October 31, 2009

Study Completion Date

January 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide once weekly

subcutaneous injection, 2.0mg, once a week

DRUG

exenatide twice daily

subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day

Trial Locations (41)

Unknown

Research Site, Birmingham

Research Site, Mesa

Research Site, Peoria

Research Site, Artesia

Research Site, Concord

Research Site, Encino

Research Site, Greenbrae

Research Site, La Mesa

Research Site, Walnut Creek

Research Site, DeLand

Research Site, Hialeah

Research Site, Miami

Research Site, New Port Richey

Research Site, Palm Harbor

Research Site, Chicago

Research Site, Avon

Research Site, Evansville

Research Site, Lexington

Research Site, Paducah

Research Site, Detroit

Research Site, Edina

Research Site, St Louis

Research Site, Butte

Research Site, New Hyde Park

Research Site, Rochester

Research Site, Raleigh

Research Site, Statesville

Research Site, Cincinnati

Research Site, Delaware

Research Site, Mentor

Research Site, Eugene

Research Site, Rapid City

Research Site, Austin

Research Site, Corpus Christi

Research Site, San Antonio

Research Site, Burke

Research Site, Manassas

Research Site, Richmond

Research Site, Olympia

Research Site, Spokane

Research Site, Tacoma

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY